| Budget Amount *help |
¥18,590,000 (Direct Cost: ¥14,300,000、Indirect Cost: ¥4,290,000)
Fiscal Year 2013: ¥5,850,000 (Direct Cost: ¥4,500,000、Indirect Cost: ¥1,350,000)
Fiscal Year 2012: ¥5,850,000 (Direct Cost: ¥4,500,000、Indirect Cost: ¥1,350,000)
Fiscal Year 2011: ¥6,890,000 (Direct Cost: ¥5,300,000、Indirect Cost: ¥1,590,000)
|
|---|
| Research Abstract |
To develop novel therapeutics for human deficiencies (lysosomal storage diseases) of lysosomal cathepsin A (CathA) and neuraminidase-1 (NEU1) based on protein-protein interaction between CathA and NEU1, we produced transgenic (Tg) silkworm strains overexpressing human CathA and NEU1 in middle silk glands, and succeeded in purification and elucidation of X-ray crystal structure of the enzymatically active CathA. The conjugates of active CathA purified from Tg silk glands and cell-penetrating peptides (R8) had replacement effects on cultured fibroblasts derived from patients with CathA deficiency (Galactosialidosis) to reduce the accumulated sialyloligosaccharides. In addition, siastatin B was found to have stabilizing effects like a chaperone compound on recombinant human cytosolic NEU2 with structural similarity to NEU1.
|
